The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Treatment and characteristics of patients treated for hepatocellular carcinoma (HCC) by physician types in the United States.
Brian S. Seal
Employment or Leadership Position - Bayer
Susan H Foltz Boklage
Employment or Leadership Position - Bayer
Carl V Asche
Consultant or Advisory Role - Bayer